CORT - CORCEPT THERAPEUTICS INC

QQQ $ 617.86 $ 0.00 (0 %)

DIA $ 471.07 $ 0.00 (0 %)

SPY $ 674.53 $ 0.00 (0 %)

TLT $ 89.97 $ 0.00 (0 %)

GLD $ 365.38 $ 0.00 (0 %)

Previous Close

$ 71.1

Open

$ 72.58

Bid

$ 60.80 x 10

Ask

$ 70.00 x 190

Day's Range

-- - --

52 Week Range

$ 49.00 - $ 117.33

Volume

1,130,153

Average Volume

Market Cap

7.48B

Beta (5Y Monthly)

$ 0.43

PE Ratio (TTM)

$ 71.45

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-04-2025	09-30-2025	10-Q
2	07-31-2025	06-30-2025	10-Q
3	05-05-2025	03-31-2025	10-Q
4	02-26-2025	12-31-2024	10-K
5	10-30-2024	09-30-2024	10-Q
6	07-29-2024	06-30-2024	10-Q
7	05-01-2024	03-31-2024	10-Q
8	02-15-2024	12-31-2023	10-K
9	11-01-2023	09-30-2023	10-Q
10	08-02-2023	06-30-2023	10-Q
11	05-03-2023	03-31-2023	10-Q
12	02-28-2023	12-31-2022	10-K
13	11-03-2022	09-30-2022	10-Q
14	08-03-2022	06-30-2022	10-Q
15	05-05-2022	03-31-2022	10-Q
16	02-15-2022	12-31-2021	10-K
17	11-03-2021	09-30-2021	10-Q
18	07-29-2021	06-30-2021	10-Q
19	05-06-2021	03-31-2021	10-Q
20	02-23-2021	12-31-2020	10-K
21	11-03-2020	09-30-2020	10-Q
22	08-04-2020	06-30-2020	10-Q
23	05-04-2020	03-31-2020	10-Q
24	02-24-2020	12-31-2019	10-K
25	11-07-2019	09-30-2019	10-Q
26	08-01-2019	06-30-2019	10-Q
27	05-09-2019	03-31-2019	10-Q
28	02-26-2019	12-31-2018	10-K
29	11-02-2018	09-30-2018	10-Q
30	08-09-2018	06-30-2018	10-Q
31	05-09-2018	03-31-2018	10-Q
32	02-28-2018	12-31-2017	10-K
33	11-03-2017	09-30-2017	10-Q
34	08-02-2017	06-30-2017	10-Q
35	05-02-2017	03-31-2017	10-Q
36	03-06-2017	12-31-2016	10-K
37	11-02-2016	09-30-2016	10-Q
38	08-03-2016	06-30-2016	10-Q
39	05-04-2016	03-31-2016	10-Q
40	03-10-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Corcept Therapeutics Lowers FY2025 Sales G...
11/04/2025 21:12:20

Corcept Therapeutics (NASDAQ:CORT) lowers FY2025 sales outlook from $850.000 million-$900.000 million to $800.000 million-$850....

Corcept Therapeutics Q3 EPS $0.16 Beats $0...
11/04/2025 21:11:40

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of ...

Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

Beyond The Numbers: 6 Analysts Discuss Cor...
10/20/2025 14:03:06

HC Wainwright & Co. Reiterates Buy on Corc...
10/20/2025 14:01:50

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...

Reported Sunday, Corcept Highlights ROSELL...
10/20/2025 07:37:58

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall su...

Corcept Submits Marketing Authorization Ap...
10/14/2025 12:08:07

In An SEC Filing On Tuesday, Corcept Thera...
10/14/2025 10:47:15

As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distributor of Korlym and t...

HC Wainwright & Co. Reiterates Buy on Corc...
10/10/2025 11:06:23

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...

4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals

4 Biotechnology Stocks That Outshine In Mo...
09/29/2025 11:11:04

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

What Analysts Are Saying About Corcept The...
09/25/2025 13:00:43

Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opin...

Canaccord Genuity Maintains Buy on Corcept...
09/25/2025 12:32:43

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ: CORT) with a Buy and maintains $140 price targ...

Corcept Therapeutics To Present New Data F...
09/22/2025 18:31:28

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...

Canaccord Genuity Maintains Buy on Corcept...
09/10/2025 14:21:15

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target fr...

FDA Accepts Corcept's NDA For Relacorilant...
09/10/2025 12:08:03

FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026Corcept Therapeutics Incorporated (NASDAQ:CORT), a co...

Canaccord Genuity Maintains Buy on Corcept...
08/01/2025 15:14:20

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target fr...

If You Invested $100 In This Stock 5 Years...
08/01/2025 15:00:24

Piper Sandler Maintains Overweight on Corc...
08/01/2025 12:08:29

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweight and lowers the price tar...

Corcept Therapeutics Lowers FY2025 Sales G...
07/31/2025 20:07:37

Financial Results"The second quarter marked another period of robust growth in our hypercortisolism business. Once again, w...

Corcept Therapeutics Q2 EPS $0.29 Beats $0...
07/31/2025 20:06:43

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of ...